Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis (NCT07193862)
🩺 Plain-English Summary (8th-Grade Level)
Microdevices have been used to ascertain in vivo drug response, which can lead to improved cancer treatment delivery; however, they have not been evaluated for liver tumors. This is a prospective, phase 1 safety study of percutaneous placement and surgical retrieval of a microdevice in patients with liver metastasis from colorectal cancer. The device will be implanted percutaneously 3-5 days prior to scheduled resection of colorectal liver metastasis (CLM) and then removed en bloc with the tumor. Patients will be monitored to ensure that the device's placement and retrieval does not result in increased complication rates within 14 days of surgery. To assess feasibility, the tissue surrounding the microdevice will be analyzed to assess the diffusion of the drugs from the device into the tissue and whether the therapeutic effect of diffusing chemotherapy +/- immune-modulating drugs has an impact on the surrounding tissue.
Who can join: Review the eligibility criteria below.
Location: RJ Zuckerberg — Lake Success, New York
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- RJ Zuckerberg — Lake Success, New York
- Long Island Jewish Medical Center — New Hyde Park, New York
📞 Contact the Study Coordinator
Phone: (833) 223-4732
Email: MWigfallMaxw@northwell.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Cancer Metastatic
- Assessing How Normal Variations in CT Scanning Affects Its Interpretation — New York, New York
- A Phase 1b Study of WU-NK-101 in Combination With Cetuximab — San Francisco, California
- Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) — Los Angeles, California
- BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases — La Jolla, California
- Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases — New York, New York
Explore by condition: All Colorectal Cancer Metastatic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.